WallStreetZenWallStreetZen

NASDAQ: IOVA
Iovance Biotherapeutics Inc Stock

$7.98-0.15 (-1.85%)
Updated Feb 3, 2023
IOVA Price
$7.98
Fair Value Price
$8.73
Market Cap
$1.26B
52 Week Low
$5.42
52 Week High
$18.73
P/E
-3.23x
P/B
3.2x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$389.90M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.39
Operating Cash Flow
-$269M
Beta
1.34
Next Earnings
Feb 22, 2023
Ex-Dividend
N/A
Next Dividend
N/A

IOVA Overview

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IOVA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IOVA ($7.98) is undervalued by 8.59% relative to our estimate of its Fair Value price of $8.73 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
IOVA ($7.98) is not significantly undervalued (8.59%) relative to our estimate of its Fair Value price of $8.73 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IOVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IOVA due diligence checks available for Premium users.

Be the first to know about important IOVA news, forecast changes, insider trades & much more!

IOVA News

Valuation

IOVA fair value

Fair Value of IOVA stock based on Discounted Cash Flow (DCF)
Price
$7.98
Fair Value
$8.73
Undervalued by
8.59%
IOVA ($7.98) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IOVA ($7.98) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IOVA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IOVA price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.23x
Industry
10.7x
Market
15.09x

IOVA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.2x
Industry
5.11x
IOVA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IOVA's financial health

Profit margin

Revenue
$0.0
Net Income
-$99.6M
Profit Margin
0%
IOVA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$545.9M
Liabilities
$152.2M
Debt to equity
0.39
IOVA's short-term assets ($369.88M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IOVA's short-term assets ($369.88M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IOVA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IOVA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$63.6M
Investing
$73.7M
Financing
$225.0k
IOVA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IOVA vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
IOVA$1.26B-1.85%-3.23x3.20x
CINC$1.28B+0.41%-1.45x2.46x
BHVN$1.24B-5.11%N/A12.37x
SAVA$1.24B-1.90%-17.27x6.23x
AUPH$1.29B-2.90%-10.90x3.04x

Iovance Biotherapeutics Stock FAQ

What is Iovance Biotherapeutics's quote symbol?

NASDAQ: IOVA) Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol IOVA. Iovance Biotherapeutics stock quotes can also be displayed as NASDAQ: IOVA.

If you're new to stock investing, here's how to buy Iovance Biotherapeutics stock.

What is the 52 week high and low for Iovance Biotherapeutics (NASDAQ: IOVA)?

(NASDAQ: IOVA) Iovance Biotherapeutics's 52-week high was $18.73, and its 52-week low was $5.42. It is currently -57.39% from its 52-week high and 47.23% from its 52-week low.

How much is Iovance Biotherapeutics stock worth today?

(NASDAQ: IOVA) Iovance Biotherapeutics currently has 157,840,581 outstanding shares. With Iovance Biotherapeutics stock trading at $7.98 per share, the total value of Iovance Biotherapeutics stock (market capitalization) is $1.26B.

Iovance Biotherapeutics stock was originally listed at a price of $110.00 in Oct 15, 2010. If you had invested in Iovance Biotherapeutics stock at $110.00, your return over the last 12 years would have been -92.75%, for an annualized return of -19.64% (not including any dividends or dividend reinvestments).

How much is Iovance Biotherapeutics's stock price per share?

(NASDAQ: IOVA) Iovance Biotherapeutics stock price per share is $7.98 today (as of Feb 3, 2023).

What is Iovance Biotherapeutics's Market Cap?

(NASDAQ: IOVA) Iovance Biotherapeutics's market cap is $1.26B, as of Feb 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Iovance Biotherapeutics's market cap is calculated by multiplying IOVA's current stock price of $7.98 by IOVA's total outstanding shares of 157,840,581.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.